ALCON
15.12.2021 17:27:08 CET | Business Wire | Press release
Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, continues its successful rollout of PRECISION1TM . The spherical lens is now available in key markets throughout Latin America and Asia, and PRECISION1 for Astigmatism is available in markets throughout Europe. PRECISION1 for Astigmatism and PRECISION1 sphere are also available throughout North America.
PRECISION1 contact lenses are designed to address the common reasons why 20% of new wearers drop out in the first three weeks: poor vision, poor comfort and handling issues.3 The lenses provide precise vision, long-lasting comfort and ease of handling to allow new wearers,1 especially those with long busy days, an exceptional lens-wearing experience.
Inspired from the water gradient lens material in DAILIES TOTAL1® , PRECISION1 is the first-and-only contact lens with Alcon’s proprietary SMARTSURFACE® Technology. This features a permanent, micro-thin, high-performance layer of moisture at the lens surface that helps support a stable tear film.4
A stable tear film is vital to visual performance and comfort, especially for contact lens wearers.5
“Reinforcing our mission to help people see brilliantly, we are proud of the PRECISION1 contact lens launch, designed for people with an on-the-go lifestyle, in many markets across the globe,” said Antoine Delgrange, Alcon Vice President for Vision Care International Marketing. “We understand the consumer journey can be challenging; so, as an added benefit, we are offering the opportunity for our customers to provide their new lens wearers with an exclusive activation program to make their introduction to contact lenses easy and enjoyable. The program includes resources to increase consumer confidence with their new lenses.”
“I think of PRECISION1 as the contact lens of the future. It’s so comfortable to wear and easy to fit that the wearing experience amazes my patients,” said Dr. Teodoro Tarud, optician and owner of Centro Óptico de la Costa, Columbia.*
The launch of PRECISION1 for Astigmatism provides a significant opportunity to attract new contact lens wearers. Studies show that 41% of patients have astigmatism that needs correction,6 but only 10% wear toric contact lenses.7 "Our patients love the comfort of PRECISION1! This is the best launch I have ever seen. We can fit more patient types now that toric and minus lenses are available," said Fiona Kavanagh, owner and optician at Jennings Opticians, Ireland.**
“We are committed to providing eye care professionals (ECPs) with a comprehensive portfolio of lens-wearing options based on the specific needs of their patients,” said Cheryl Donnelly, International Head of Professional Affairs at Alcon. “Now, with PRECISION1 and PRECISION1 for Astigmatism, ECPs and optical retailers can offer more lens wearers a next-generation contact lens with exceptional all-day performance.”
For more information, visit PRECISION1® One-Day Contact Lenses | PRECISION1® (myalcon.com)
Cautionary Note Regarding Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “commitment,” “look forward,” “maintain,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods.
Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties and risks that are difficult to predict. Some of these factors are discussed in our filings with the United States Securities and Exchange Commission, including our Form 20-F. In particular, our expectations could be affected by uncertainties regarding the success of our separation and spin-off from Novartis. Should one or more of these uncertainties or risks materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated. Therefore, you should not rely on any of these forward-looking statements.
Forward-looking statements in this press release speak only as of the date of its filing, and we assume no obligation to update forward-looking statements as a result of new information, future events or otherwise.
About Alcon
Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning more than seven decades, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 23,000 associates are enhancing the quality of life through innovative products, partnerships with eye care professionals and programs that advance access to quality eye care. Learn more at www.alcon.com .
* Teodoro Tarud is a paid Alcon consultant.
** Fiona Kavanagh is a paid Alcon consultant.
References
- Grant T, Tang A. A Survey of contact lens wearers and eye care professionals on satisfaction with a new smartsurface silicone hydrogel daily disposable contact lens. Clin Optom 2020;12:9–15.
- In a clinical study, wherein subjects were fitted with PRECISION1 for Astigmatism contact lenses (N=78 eyes); Alcon data on file, 2020.
- Sulley A, Young G, Hunt C, et al. Retention rates in new contact lens wearers. Eye & Contact Lens. 2018;44:S273-S282.
- In vitro analysis of verofilcon A contact lenses for surface properties; Alcon data on file 2019.
- Craig JP, Willcox MDP, Argueso P, et al. The TFOS international workshop on contact lens discomfort: Report of the contact lens interactions with tear film subcommittee. Invest Ophthalmol Vis Sci. 2013; 54:TFOS123-TFOS156.
- Luensmann D, Schaeffer J, Rumney N, et al. Spectacle prescriptions review to determine prevalence of ametropia and coverage of frequent replacement soft toric contact lenses. Contact Lens and Anterior Eye ; 2018; 41 (5); 412-420.
- Multi-Sponsor Surveys 2014 Gallup target market report.
Connect with us on
View source version on businesswire.com: https://www.businesswire.com/news/home/20211215005725/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease1.5.2026 23:28:00 CEST | Press release
Jakafi XR is a once-daily, film-coated, extended-release formulation of Jakafi®(ruxolitinib)Once-daily Jakafi XR was shown to provide consistent, day-long exposure comparable to twice-daily JakafiJakafi XR will be available for pharmacy orders by May 8 Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Jakafi XR™ (ruxolitinib) extended-release tablets for the treatment of adults with intermediate- or high-risk myelofibrosis (MF); adults with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea; as well as adults and children aged 12 years and older with steroid-refractory acute graft-versus-host disease (GVHD) or chronic GVHD after failure of one or two lines of systemic therapy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260501334677/en/ “The approval of Jakafi XR reinforces Incyte’s leadership in hematology and our focus on meetin
Barilla Hosts Surprise Formula 1® Family Reunion Dinner During Miami Race Weekend1.5.2026 18:08:00 CEST | Press release
Drivers and team members of Formula 1® were reunited with their loved ones during a night that also celebrated the new partnership between Barilla and the Visa Cash App Racing Bulls Formula 1® Team. A special invitation, a table, and a plate of pasta shared by people who are often apart. That’s all it took for Barilla to bring the spirit of togetherness to Miami during the opening day of the FORMULA 1® CRYPTO.COM MIAMI GRAND PRIX 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430832316/en/ Barilla hosts Arvid Lindblad, Mikaela Shiffrin, and Nico Rosberg with Chef Massimo Bottura at Torno Subito, where the Formula 1® community came together for a surprise dinner. Barilla, the Official Pasta Partner of Formula 1®, welcomed team members and their families to Torno Subito Miami, the restaurant by three-Michelin-starred Chef Massimo Bottura, with the kitchen led by Chef Bernardo Paladini, for an evening where engines wer
TIME Names Xenco Medical one of the TIME100 Most Influential Companies in the World and the Winner of the 2026 TIME100 Impact Award in Health1.5.2026 12:07:00 CEST | Press release
Time Magazine has named pioneering medical technology company Xenco Medical as one of the TIME100 Most Influential Companies in the World and the Winner of the 2026 TIME100 Impact Award in Health. Widely regarded as the most prestigious recognition in business and technology, being selected to the TIME100 List remains the most coveted accolade that a company can achieve globally. The TIME100 Impact Awards are given to only 5 recipients each year, making it the rarest of honors that a company can receive and a profound recognition of transformative, global impact. Xenco Medical was honored by Time as the sole recipient of the TIME100 Impact Award in Health in 2026, signifying its leading, global distinction in impact on healthcare. According to Time Magazine, the TIME100 Most Influential Companies list highlights “companies making an extraordinary impact around the world.” The honor bestowed by Time comes after Xenco Medical was named the 2025 Medical Device/ Diagnostics Company of the
Andersen Consulting styrker sine kompetencer inden for digital transformation med Weexa1.5.2026 10:07:00 CEST | Pressemeddelelse
Andersen Consulting indgår en samarbejdsaftale med Weexa, en global leverandør af løsninger inden for digital transformation, B2B-integration og digitalisering af forsyningskæden. Med hovedsæde i Frankrig leverer Weexa end-to-end-tjenester, der hjælper organisationer med at optimere, sikre og skalere deres digitale økosystemer. Virksomheden specialiserer sig i styring af B2B-datastrømme og digitalisering, hvilket muliggør problemfri kommunikation mellem applikationer både internt og på tværs af organisationer gennem teknologier som EDI, API'er og e-fakturering. Weexa tilbyder også SAP-integration og supply chain-løsninger til styring af lager og transport, sideløbende med strategisk rådgivning, projektlevering og vedligeholdelse af tredjepartsapplikationer. Weexa betjener organisationer inden for fødevaresektoren, detailhandel, engros, logistik, transport, bilindustrien, sundheds- og mediesektoren og hjælper globale virksomheder med at optimere deres ydeevne samt at overholde de nyeste
Inspirit Capital Completes Acquisition of Kaplan Languages Group1.5.2026 01:17:00 CEST | Press release
Inspirit Capital, a specialist investor in corporate carve-outs, and Kaplan, the global education company, have announced the completion of Inspirit’s acquisition of Kaplan Languages Group (KLG) from Kaplan. Financial terms are not being disclosed. KLG, a leading global language education platform, comprises Kaplan International Languages, Alpadia Language Schools, Azurlingua, and ESL Education. Inspirit Capital will support KLG in delivering on its ambitious growth plans, whilst continuing its fundamental mission to transform lives through language education. The next phase of ownership will see the development and launch of a refreshed standalone brand identity for KLG, with further announcements to follow on this in due course. KLG will continue to use the Kaplan name under a transitional license from Kaplan, Inc. until a new brand is announced. About Kaplan Languages Group Since 2006, KLG has provided the highest quality language education and cultural immersion experiences. Kaplan
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
